The investigational Aurora kinase A inhibitor alisertib (MLN8237) induces cell cycle G(2)/M arrest, apoptosis, and autophagy via p38 MAPK and Akt/mTOR signaling pathways in human breast cancer cells

Alisertib (ALS) is an investigational potent Aurora A kinase inhibitor currently undergoing clinical trials for the treatment of hematological and non-hematological malignancies. However, its antitumor activity has not been tested in human breast cancer. This study aimed to investigate the effect of...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Jin-Ping, Yang, Yin-Xue, Liu, Qi-Lun, Pan, Shu-Ting, He, Zhi-Xu, Zhang, Xueji, Yang, Tianxin, Chen, Xiao-Wu, Wang, Dong, Qiu, Jia-Xuan, Zhou, Shu-Feng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2015
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4365748/
https://www.ncbi.nlm.nih.gov/pubmed/25834401
http://dx.doi.org/10.2147/DDDT.S75378

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4365748/
https://www.ncbi.nlm.nih.gov/pubmed/25834401
http://dx.doi.org/10.2147/DDDT.S75378

Ejemplares similares